To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs — those that address unmet medical needs — based on fewer trials than usual. But it turns out that many of the pharmaceutical companies fail to conduct follow-up trials to prove the drugs work.
Continue reading The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up
The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up originally appeared on DailyFinance on Wed, 09 Feb 2011 20:00:00.
Filed Under: Health Care, Genzyme Corporation , GlaxoSmithKline, Novartis, Amgen, Eli Lilly